Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sumatriptan succinate
Drug ID BADD_D02099
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage A combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
Marketing Status approved; investigational
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00676
MeSH ID D018170
PubChem ID 59772
TTD Drug ID D0Z6UC
NDC Product Code 52932-0727; 62331-049; 65862-146; 65862-148; 50090-1130; 53002-1592; 55111-693; 0378-5631; 72189-432; 0093-2014; 49574-517; 53104-7581; 53002-2592; 62756-522; 50370-0014; 51552-1376; 55111-060; 65015-860; 65015-864; 16714-796; 43598-768; 51407-011; 51407-013; 62756-520; 63187-931; 68071-2283; 60429-994; 62756-521; 63187-607; 71205-111; 49452-7585; 65862-147; 51407-012; 53002-1562; 53002-2593; 55700-759; 55700-899; 63187-049; 63187-617; 0378-5630; 76420-499; 35356-439; 42847-311; 55111-293; 63187-797; 68788-6778; 70518-1184; 0378-5632; 62756-730; 16714-797; 47335-276; 0245-0809; 55111-291; 55111-292; 63187-969; 68788-9547; 70594-068; 76420-093; 53069-0560; 57315-216; 67835-5010; 16714-798; 50090-2144; 70518-1183; 71205-251; 71205-725; 76420-498; 76420-500; 59651-151; 71205-274; 72189-433; 72603-141; 0093-2013; 65862-371; 50090-1129; 50090-5939; 53002-1593; 53002-2562; 63323-273; 68788-6769; 68788-8205; 70518-2859; 48087-0075; 57315-214; 57315-215; 16714-040; 45865-570; 55700-936
UNII J8BDZ68989
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C18H27N3O6S
CAS Registry Number 103628-48-4
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypopnoea22.02.01.021---
Hypotension24.06.03.002--
Hypothyroidism05.02.03.001; 14.11.01.012--
Influenza11.05.03.001; 22.07.02.001---
Intestinal obstruction07.13.01.002---
Intracranial pressure increased17.07.02.002---
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Liver function test abnormal13.03.04.030---
Lower respiratory tract infection11.01.09.002; 22.07.01.002---
Lymphadenopathy01.09.01.002---
Malaise08.01.01.003--
Mass08.03.05.003---
Melaena07.12.02.004; 24.07.02.013---
Memory impairment17.03.02.003; 19.20.01.003--
Meniere's disease04.04.02.003; 07.01.07.007; 17.02.12.003---
Menstrual disorder21.01.01.004---
Micturition disorder20.02.02.005---
Monoplegia17.01.04.003---
Muscle rigidity15.05.04.001; 17.05.02.005---
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005---
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Mydriasis06.05.03.004; 17.02.11.003---
Myocardial ischaemia02.02.02.008; 24.04.04.010---
Myoclonus17.02.05.008---
Myositis15.05.01.001--
Nasal inflammation22.04.04.002---
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages